The distinction between mantle cell lymphoma (MCL) and other small B-cell non-Hodgkin lymphomas (NHL) is important because MCL has a more aggressive clinical course. In bone marrow (BM) biopsy specimens, this distinction can be particularly difficult. Although cyclin D1 immunostaining and molecular detection of the t(11;14) translocation are highly specific markers for MCL, they fail to detect a proportion of cases. We have recently described that MCL typically lacks detectable expression of the cyclin-dependent kinase inhibitor p27 kip1 protein by immunostaining, which is expressed at high levels in most small B-cell NHL inversely correlated to the proliferation rate. We therefore examined whether p27 kip1 immunostaining could be a useful adjunct for the differential diagnosis of small B-cell NHL infiltrates in the BM. Trephine BM biopsy specimens of 96 patients, including well-characterized MCL (19 cases), B-cell chronic lymphocytic leukemia (27 cases), follicular lymphoma (18 cases), hairy cell leukemia (22 cases), and marginal zone lymphoma (10 cases) as well as 10 reactive BM, including five with benign lymphoid aggregates were investigated. In addition, the presence of a t(11;14) translocation involving the major translocation cluster was studied by PCR in all MCL. All cases of B-cell chronic lymphocytic leukemia, follicular lymphoma, and marginal zone lymphoma revealed a strong p27 kip1 nuclear staining in the majority of neoplastic cells. Fourteen (78%) cases of MCL were p27 kip1 -negative in the tumor cells, whereas four cases revealed a weak nuclear positivity. Seventeen (77%) cases of hairy cell leukemia were also either completely negative for p27 kip1 or showed a faint positive staining in a minority of the neoplastic cells. Nine of 19 cases (47%) of MCL showed a bcl1 rearrangement involving the major translocation cluster region. These findings demonstrate that p27 kip1 immunostaining is a valuable additional marker for the differential diagnosis of small B-cell NHL infiltrates in BM biopsies. The reduction or lack of p27 kip1 protein expression in MCL, as well as in hairy cell leukemia, might be an important event in the pathogenesis of these disorders.
conventional therapeutic regimens and a median survival duration of 3 to 4 years (8, 9) . Like other small B-cell NHL, the majority of patients present with advanced disease, including generalized lymphadenopathy and BM involvement (8, 10 -12) . Therefore, the distinction of MCL from other B-cell neoplasms in BM biopsies is of significant clinical relevance. Immunohistochemical demonstration of cyclin D1 protein is an important marker for the diagnosis of MCL, because it is expressed neither in normal lymphocytes nor in most B-cell NHL (6, 8, 13, 14) . However, cyclin D1 staining can be capricious in decalcified BM biopsies, and false negative results may lead to misclassification of lymphoma infiltrates (6, 15, 16) . p27 kip1 is a cyclin-dependent kinase inhibitor which is crucial for cell cycle progression from G1 into S phase (17, 18) . Deregulation of p27
Kip1 expression is a relatively common feature in many solid tumors, but alterations of the gene are infrequent (19 -22) . We and others have recently observed that the lack or reduction of p27Kip1 protein expression is a characteristic feature of MCL, in contrast to other small B-cell NHL, in which p27 Kip1 is strongly expressed (23) (24) (25) . We therefore investigated the utility of p27 Kip1 immunostaining for the differential diagnosis of small B-cell NHL infiltrates in routinely processed BM biopsies.
MATERIALS AND METHODS

Tissue Samples
Trephine BM biopsy specimens of 96 patients were selected from the files of the Institutes of Pathology of the University of Innsbruck, Austria, the Technical University of Munich, Germany, and the General Hospital Salzburg, Austria. All cases were classified according to the Revised EuropeanAmerican Lymphoma and the upcoming WHO classifications (7, 26) . They included 19 cases of MCL, of which 18 were classified as typical MCL and 1 as blastic variant of MCL (27) , 27 cases of B-cell chronic lymphocytic leukemia (B-CLL)/small lymphocytic leukemia (SLL), 18 cases of follicular lymphoma (FL) (grades I and II), 22 cases of hairy cell leukemia (HCL), and 10 cases of marginal zone lymphoma (MZL). As controls, 10 BM biopsies with reactive changes, including five BM biopsies with reactive nodular lymphoid infiltrates, partially with germinal centers were analyzed. Additional lymph node (LN) biopsies were investigated in five cases of MCL.
The primary diagnosis of MCL, FL, and MZL had been made on LN biopsies or extranodal tumor infiltrates thoroughly characterized by paraffin section immunostaining. For a diagnosis of HCL, expression of CD103 was demonstrated on BM frozen sections, in addition to standard morphologic criteria and paraffin immunostaining including monoclonal antibody DBA 44 (28 -30) . Cases of B-CLL/SLL had been immunophenotyped by flow cytometry of peripheral blood or BM samples.
BM samples were formaldehyde (4%) fixed (pH 7.4) for at least 24 hours and decalcified with buffered sodium-ethylenediaminetetra-acetic acid (pH 7.0) for 48 hours. Four to five m thick sections were cut, stained with hematoxylin and eosin, Giemsa, periodic acid-Schiff, Gomori's reticulin stain, and Naphtol AS-D chloroacetate esterase.
Immunohistochemistry
All cases were stained for cyclin D1 (clone P2D11F11, Novocastra, Newcastle, UK; dilution 1:10), CD20 (DAKO, Copenhagen, Denmark; dilution 1:500) and polyclonal CD3 (DAKO; dilution 1:200). The expression of p27
Kip1 was investigated with the monoclonal antibody Kip-1 (Transduction Laboratories, Lexington, KY; dilution 1:1000). Moreover, in selected cases stains for CD10 (Novocastra; dilution 1:10), CD5 (clone 4C7, Novocastra; dilution 1:50), CD23 (Novocastra; dilution 1:50), and MiB-1 (Dianova, Hamburg, Germany) were accomplished.
Immunohistochemistry was performed on an automated immunostainer (Ventana Medical Systems, Tucson, AZ) according to the manufacturer's protocols, with minor modifications (24) . After deparaffinization and rehydration, the slides were placed in a microwave pressure cooker in 0.01 mol/L citrate buffer (pH 6.0) containing 0.1% Tween 20 and heated in a microwave oven at maximum power (800W) for 35 minutes. The sections were immediately cooled in Tris-buffered saline and washed in 3% goat serum for 20 minutes. Incubations with the primary antibodies were performed overnight at room temperature. The rest of the procedure was completed on the Ventana immunostainer.
Positive controls for all investigated antibodies were used to confirm the adequacy of the staining. The staining quality of cyclin D1 was verified by a cyclin D1-positive MCL, carrying a t(11;14) translocation. Furthermore, scattered positive endothelial cells served as internal control. For the comparison of p27
Kip1 staining between tissue samples, T-cells were used as internal controls.
Double immunostaining was also performed on representative cases to more precisely evaluate the coexpression of p27
Kip1 with B-(CD20) and T-(CD3) cell markers. For these reactions, p27 Kip1 was detected as described above followed by 2 hours of incubation with CD20 or CD3 antibodies, respectively. The second reaction was developed using the Elite-ABC-Kit and VIP substrate (Vector laborato- ries, Burlingame, CA, USA) resulting in a contrasting dark purple precipitate.
All immunohistochemical stainings were reviewed by three pathologists (MK, LQ-M, FF). Because cyclin D1 expression is undetectable in normal lymphatic cells, all unequivocal, nuclear staining in tumor cells was classified as positive. For p27 Kip1 protein expression, the staining intensity was graded as negative, weak, moderate and strong; strong staining was defined as being of comparable intensity to reactive T-cells and plasma cells. A lymphoma was considered as p27 Kip1 -positive, if at least 20% of the neoplastic cells showed any nuclear staining.
Detection of bcl1 Translocations by PCR Analysis
In all MCL cases and in the HCL cases showing positivity for cyclin D1, the presence of translocations involving the bcl1/JH major translocation cluster (MTC) was assessed by PCR using a previously published protocol (31) . Briefly, DNA was extracted from paraffin-embedded BM and LN biopsy specimens. The tissue was dewaxed, and digested by overnight proteinase K incubation (20 mg/mL) at 55°C. Amplification was performed using a consensus JH primer 5'-ACC TGA GGA GAC GGT GAC CAG GGT-3' and one of two MTC region primers, MTC1 5'-CCT CTC TCC AAA TTC CTG-3' and MTC2 5'-GAT GGG CTT CTC TCA CCT ACT A-3'. Forty cycles of amplification under previously established, optimized conditions were performed. The product was electrophoresed in a 2% agarose gel, stained with ethidium bromide, and photographed under ultraviolet light. Selected positive cases were analyzed by direct sequencing to confirm the specificity of the amplification product. Stringent laboratory protocols were followed to prevent PCR product contamination. A well characterized MCL served as positive control, and was included in every run.
RESULTS
Immunohistochemical Findings
P27Kip1 Protein Expression in Reactive BM Samples
In normal BM, p27 Kip1 protein was expressed in the nuclei of most megakaryocytes, as well as in endothelial cells, plasma cells and small reactive T-lymphocytes. All other hematopoietic cells were negative for p27
Kip1 (32) . Reactive nodular lymphoid infiltrates showed strong p27
Kip1 protein expression, whereas germinal centers where negative for p27 Kip1 .
p27Kip1 and Cyclin D1 Protein Expression in MCL
Fourteen of the 18 cases (78%) of classical MCL were classified as negative for p27 Kip1 , showing either a faint reactivity of tumor cells in two cases (15%) or complete lack of staining in 12 cases (85%). In all cases, scattered small lymphocytes strongly positive for p27 Kip1 were identified. Serial sections stained for CD3, as well as double stainings revealed that these p27 Kip1 -positive small lymphocytes were reactive T cells (Fig. 1, A-D) . In the remaining four cases, the majority of the neoplastic cells were weakly p27 Kip1 -positive, at a significantly lower intensity than the scattered T cells. The single case of blastic variant of MCL weakly expressed p27
Kip1 in most tumor cells despite a high proliferation index as assessed by MiB1 staining (more than 80%). Nuclear cyclin D1 expression was demonstrated in all but two cases (89%). However, the staining was weak and heterogeneous in many BM biopsies, making interpretation problematical. Both MCL cases negative for cyclin D1 in the BM were cyclin D1 positive in the diagnostic LN biopsy examined in parallel. In addition, one of these two cases showed a bcl1 rearrangement by PCR (Table  1) . Both cases were p27
Kip1 -negative in the BM, supporting a diagnosis of MCL. Kip1 nuclear staining in the vast majority of tumor cells, similar to the intensity seen in T lymphocytes (Fig. 1, E-G) . Occasional transformed cells in FLs and B-CLLs were p27 Kip1 -negative. Cyclin D1 protein was undetectable in all examined cases of these lymphoma subtypes.
HCL represented a distinct group set apart from the other small B-cell NHL. Five of 22 cases (23%) showed a weak to moderate p27
Kip1 reactivity in more than 50% of the neoplastic cells, but less strong than plasma cells and scattered T lymphocytes (Figure 1, H-J) . Seventeen cases (77%) of HCL were classified as negative for p27 Kip1 , showing either a faint reactivity in rare cells (eight cases), or complete lack of staining in neoplastic cells (nine cases) ( Table 2 ). The proliferation activity of neoplastic cells was very low, as assessed by immunostaining for MiB1.
Cyclin D1 protein expression was detectable in nine cases (41%). Three cases (13%) showed a weak to moderate nuclear staining in the majority of the tumor cells, whereas six cases (27%) revealed a mostly weak nuclear staining in a minority of the neoplastic cells.
Molecular Analysis
PCR amplification of DNA extracted from tissues of the 19 MCL cases revealed strong bands of appropriate size in 9 (47%) of 19 cases, confirming the presence of a bcl1 translocation involving the MTC (Fig. 2) . In Cases 2 and 3 (Table 1) , PCR failed to detect the bcl1 rearrangement in the BM and LN, respectively, irrespective of a reproducible positive signal in the additionally investigated tissues from the same patients. This discrepancy is most probably due to insufficient DNA quality in the formalinfixed samples, because the expected product sizes are between 370 and 600 base pairs. As expected, the investigated nine HCL failed to show a bcl1 translocation.
DISCUSSION
Our study demonstrates that immunohistochemical detection of p27
Kip1 protein is a valuable marker for the differential diagnosis of B-cell NHL infiltrates in BM biopsies. The consistent lack of p27 Kip1 protein expression allows the distinction of MCL from other small B-cell NHL, which constantly show a strong p27
Kip1 reactivity with the notable exception of HCL. However, p27
Kip1 protein expression does not discriminate between reactive and neoplastic lymphoid nodular infiltrates in the BM, with the exception of MCL.
The classification of small B-cell lymphomas in the BM is a common diagnostic problem resulting from overlapping morphologic features (1, 3, 6, 15) . The distinction of MCL from other entities is clinically important because of its poor response to therapy and its unfavorable prognosis (8) . Since of the description of cyclin D1 overexpression as a consistent feature of MCL and the availability of antibodies suitable for paraffin-embedded tissue, immunostaining for cyclin D1 has become an important adjunct for the diagnosis of MCL (8, 13, 15, 33) . Nevertheless, immunohistochemical demonstration of cyclin D1 can be capricious, especially in routinely processed and decalcified BM biopsy specimens, and a negative result does not rule out a diagnosis of MCL (6, 16) . Even in well fixed and paraffin-embedded LN biopsies, immunohistochemistry fails to detect cyclin D1 protein in 10 to 30% of MCL (6, 15) . In addition, the choice of fixative and decalcification procedure for BM biopsies is critical for cyclin D1 staining. Fixation in a 1% formaldehyde solution containing 0.4% glutaraldehyde, a BM fixative widely used in Germany, completely abolishes staining for cyclin D1 (data not shown). Although molecular demonstration of a bcl1 rearrangement can resolve some of the cases, PCR and even Southern blot analysis fail to identify a significant number of cases due to the wide distribution of breakpoints outside the MTC (34) . Amplification of the MTC by PCR renders a positive result only in 33 to 50% of MCL cases in paraffinembedded specimens (31, (35) (36) (37) . Our detection rate of 47% is consistent with these published data. Keeping these diagnostic difficulties in mind, we decided to analyze whether the characteristic lack of p27
Kip1 immunostaining in MCL can be exploited for the differential diagnosis of BM biopsies involved in lymphoma (24, 25) .
In accordance with our previous study, a lack or significant reduction of p27
Kip1 immunostaining in a CD5-positive small B-cell neoplasia is highly suggestive of MCL, whereas a strong, homogeneous expression practically rules out this diagnosis (24) . The usefulness of additional p27
Kip1 staining for a diagnosis of MCL is documented by two of our cases, which were negative for cyclin D1 in the BM. In both of them, the diagnosis of MCL was confirmed by a positive cyclin D1 staining in the additionally investigated primary LN biopsy. Both of them showed a negative p27
Kip1 staining in the BM, underlining the value of this antibody for difficult cases. However, the strong positivity of reactive T-cells has to be taken into consideration for a correct interpretation of p27
Kip1 stains. For small B-cell NHL infiltrates with a high number of infiltrating reactive T-lymphocytes, careful comparison with an adjacent section stained for T-cells is necessary.
Whereas MCL characteristically shows absence or significant reduction of immunodetectable p27 Kip1 , with the exception of the blastic variant of MCL, small B-cell NHL show high expression of p27 Kip1 in strictly inverse correlation to the proliferation rate (23) (24) (25) . The absence of p27
Kip1 protein in MCL is not due to gross rearrangements or deletion of the p27 Kip1 gene, and the mRNA levels of p27
Kip1 are in a normal range (24, 25) . Recently, it has been proposed that an increased degradation of p27
Kip1 protein via the proteasome pathway might be an explanation for this phenomenon (25) .
Unexpectedly and similar to MCL, HCL lacks p27
Kip1 expression irrespective of a generally very low proliferation rate. In our study, the majority of HCL cases (77%) showed low or undetectable levels of p27 Kip1 , and in the remaining positive cases the intensity of immunostaining was less than in the reactive T-and plasma cells. This finding confirms a recently published study by Chilosi et al., who investigated 58 HCL and found a lack of p27 Kip1 protein expression in nearly all of them (93%) (38) . The reason for the lack of p27
Kip1 protein expression in HCL is unclear. In contrast to MCL and epithelial neoplasms, no increased p27
Kip1 degradation was observed (25, 38) . A common feature of both MCL and HCL is cyclin D1 protein overexpression. There is a considerable variation in the rate of cyclin D1 positivity reported for HCL, ranging from as little as 6% to 100% in different studies (6, 14, 39, 40) . These results are probably due to the use of different antibodies and antigen retrieval techniques. Our rate of 41% positivity for cyclin D1 is in accordance with these data. In contrast to MCL, overexpression of cyclin D1 in HCL is not due to alterations involving the 11q13 region (39, 41, 42) . Whether the overexpression of cyclin D1 in these two otherwise distinct B-cell neoplasms could hint to common mechanisms responsible for the absence or reduction of immunodetectable p27 Kip1 protein remains to be determined. In terms of differentiation between MCL and HCL, the common lack of p27 kip1 expression should not pose diagnostic problems, due to the characteristic morphology and CD5 negativity of HCL.
In conclusion, our findings demonstrate that the consistent lack of p27 kip1 protein expression allows the distinction of MCL from other small B-cell NHL, making p27 kip1 immunostaining a valuable additional marker for the differential diagnosis of small B-cell NHL infiltrates in BM biopsies. This text is well illustrated with numerous clinical photographs as well as both black and white and color photomicrographs. It covers almost every condition that occurs in the head and neck region with the exception of cervical lymphoid lesions. The text is site-specific, including lesions of the sinonasal area and ear to oral, nasopharyngeal, salivary gland, laryngeal, thyroid, and neck diseases.
The uniqueness of this text is the collaborative effect of pathologists with expertise in the head and neck region and clinicians with surgical excellence in otolaryngology. This combination of expertise results in an excellent resource for medical students, pathologists, otolaryngologists, and others diagnosing or treating diseases of the head and neck region.
Each chapter typically includes a section on clinical consideration and pathology. The clinical portion discusses diagnosis and treatment, often including suggested imaging, surgical techniques, and alternative therapy. The pathology section includes gross and microscopic pathology, including immunohistochemical techniques and differential diagnoses. Although photomicrographs are generally excellent and helpful in making a diagnosis, they are not a substitute for more detailed surgical pathology texts, atlases, and fasicles. The same would be true for detailed information on surgical techniques or alternative management modalities.
Another excellent feature of this text is the number of references for each chapter section. Most are extensive and current, with several containing more than 500 entries.
A deficiency of the text is the repetitive discussion of the same diseases in multiple areas without adequate cross-referencing. For example, Wegener's granulomatosis is discussed in six different areas with only one reference to another area. This was frustrating for many conditions because some site areas had a detailed discussion with good photomicrographs, while other areas left the reader referring back to the index for additional information.
As an Oral and Maxillofacial Pathologist with 30 years of experience in head and neck diseases, I learned new information in almost every chapter. The text is a valuable reference for both pathologists and clinicians, and I would highly recommend it for the clinical-pathologic correlation.
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